The analysis highlights Abbott's status as a Dividend King, having increased its dividend for 54 consecutive years. The company reported Q2 sales of $12.6 billion, up 13% year-over-year, with adjusted diluted EPS of $1.31, beating Wall Street expectations. Abbott also raised its full-year adjusted EPS forecast to between $5.45 and $5.60 per share, supported by growth in its medical devices and cancer diagnostics businesses. Wall Street analysts generally rate ABT a "strong buy."